AKBA · Insider Trading
Akebia Therapeutics, Inc.
Every open-market purchase and sale reported by AKBA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-10 | John P. Butler | CEO and President | M | — | — |
| 2026-07-01 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | Sell | — | — |
| 2026-06-22 | Myles Wolf | Director | A | — | — |
| 2026-06-22 | MICHAEL W ROGERS | Director | A | — | — |
| 2026-06-22 | LEANNE M ZUMWALT | Director | A | — | — |
| 2026-06-22 | RON FRIESON | Director | A | — | — |
| 2026-06-22 | Cynthia Smith | Director | A | — | — |
| 2026-06-22 | ADRIAN ADAMS | Director | A | — | — |
| 2026-04-03 | Philip J. Vickers | Director | A | — | — |
| 2026-03-05 | John P. Butler | CEO and President | Buy | — | — |
| 2026-02-04 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | Sell | — | — |
| 2026-02-04 | Steven Keith Burke | SVP, Chief Medical Officer | Sell | — | — |
| 2026-02-04 | Richard C Malabre | SVP, Chief Accounting Officer | Sell | — | — |
| 2026-02-04 | John P. Butler | CEO and President | MIXED | — | — |
| 2026-02-04 | Nicholas Grund | Chief Commercial Officer | Sell | — | — |
| 2026-02-04 | Carolyn M. Rucci | SVP, Chief Legal Officer | Sell | — | — |
| 2026-02-03 | Steven Keith Burke | SVP, Chief Medical Officer | A | — | — |
| 2026-02-03 | Carolyn M. Rucci | SVP, Chief Legal Officer | A | — | — |
| 2026-02-03 | Nicholas Grund | Chief Commercial Officer | A | — | — |
| 2026-02-03 | John P. Butler | CEO and President | A | — | — |
| 2026-02-03 | Richard C Malabre | SVP, Chief Accounting Officer | A | — | — |
| 2026-02-03 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | A | — | — |
| 2025-07-01 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | Sell | — | — |
| 2025-06-11 | RON FRIESON | Director | A | — | — |
| 2025-06-11 | LEANNE M ZUMWALT | Director | A | — | — |
| 2025-06-11 | STEVEN C GILMAN | Director | A | — | — |
| 2025-06-11 | Myles Wolf | Director | A | — | — |
| 2025-06-11 | Richard C Malabre | SVP, Chief Accounting Officer | MIXED | — | — |
| 2025-06-11 | MICHAEL W ROGERS | Director | A | — | — |
| 2025-06-11 | ADRIAN ADAMS | Director | A | — | — |
| 2025-06-11 | Cynthia Smith | Director | A | — | — |
| 2025-06-05 | Richard C Malabre | SVP, Chief Accounting Officer | Sell | — | — |
| 2025-03-04 | Steven Keith Burke | SVP, Chief Medical Officer | Sell | — | — |
| 2025-03-04 | John P. Butler | CEO and President | Sell | — | — |
| 2025-02-04 | Richard C Malabre | SVP, Chief Accounting Officer | MIXED | — | — |
| 2025-02-04 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | A | — | — |
| 2025-02-04 | Nicholas Grund | Chief Commercial Officer | MIXED | — | — |
| 2025-02-04 | John P. Butler | CEO and President | MIXED | — | — |
| 2025-02-04 | Steven Keith Burke | SVP, Chief Medical Officer | MIXED | — | — |
| 2025-01-22 | RON FRIESON | Director | M | — | — |
| 2024-07-02 | Erik Ostrowski | SVP, CFO, CBO & Treasurer | A | — | — |
| 2024-06-10 | Cynthia Smith | Director | A | — | — |
| 2024-06-10 | MICHAEL W ROGERS | Director | A | — | — |
| 2024-06-10 | ADRIAN ADAMS | Director | A | — | — |
| 2024-06-10 | STEVEN C GILMAN | Director | A | — | — |
| 2024-06-10 | RON FRIESON | Director | A | — | — |
| 2024-06-10 | LEANNE M ZUMWALT | Director | A | — | — |
| 2024-06-10 | Myles Wolf | Director | A | — | — |
| 2024-05-14 | Michel Dahan | SVP, Chief Operating Officer | Sell | — | — |
| 2024-05-14 | Nicole R. Hadas | SVP, Chief Legal Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | CEO and President | 3,878,492 | — |
| — | Director | 3,037,042 | — |
| — | 10%+ Owner | 1,516,387 | — |
| — | SVP, Chief Medical Officer | 969,133 | — |
| — | SVP, Chief Operating Officer | 672,092 | — |
| — | SVP, Chief Legal Officer | 651,243 | — |
| — | SVP, CFO, CBO & Treasurer | 616,616 | — |
| — | SVP, Chief Legal Officer | 615,922 | — |
| — | Chief Commercial Officer | 561,750 | — |
| — | SVP, CFO and Treasurer | 519,300 | — |
| — | Chief Medical Officer | 512,096 | — |
| — | SVP, CFO and Treasurer | 446,483 | — |
| — | SVP, Chief Accounting Officer | 312,772 | — |
| — | Director | 236,200 | — |
| — | SVP, Chief Accounting Officer | 219,954 | — |
| — | Director | 197,429 | — |
| — | Director | 196,633 | — |
| — | 10%+ Owner | 182,590 | — |
| — | SVP, CCO | 180,546 | — |
| — | Director | 169,081 | — |
| — | Director | 165,200 | — |
| — | Director | 152,830 | — |
| — | Director | 145,100 | — |
| — | SVP, CFO & Treasurer | 144,642 | — |
| — | SVP, Chief Medical Officer | 96,332 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AKBA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.